Journal
CANCERS
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/cancers11081152
Keywords
liquid biopsy; cfDNA; pancreatic cancer; precision medicine; circulating tumor cells (CTC)
Categories
Funding
- University of Verona
- University of Verona Internalization Program Cooperint
- Associazione Italiana Ricerca Cancro (AIRC) [12182]
- European Community Grant Transcan Bio-PaC
- FP7 European Community Grant Cam-Pac [602783]
- Italian Health Ministry [RF-2013-02359692]
Ask authors/readers for more resources
Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available